US equities |
NVDA $162.49 ▼-2.23% AMD $549.61 ▼-6.10% MU $780.98 ▼-2.19% TSLA $393.94 ▼-0.88% SNDK $887.54 ▼-5.33% AAPL $359.83 ▲+1.40% MSFT $522.89 ▼-0.02% SPCX $139.69 ▼-0.18%
FinancialContent

MiNK Therapeutics, Inc. - Common Stock (NQ:INKT)

9.400 -0.130 (-1.36%)
Delayed Quote Updated: 9:44 AM EST, Nov 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,557
Open 9.680
Bid (Size) 8.930 (100)
Ask (Size) 9.590 (100)
Prev. Close 9.530
Today's Range 9.400 - 9.680
52wk Range 8.480 - 16.93
Shares Outstanding 34,422,063
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
MiNK Therapeutics (INKT) Q3 2026 Earnings Call Transcript ↗
First revenue lands as the ARDS trial enters randomized Phase II. 
Via The Motley Fool
Topics Earnings
News headline image
What MiNK Therapeutics (INKT) Said on Its Q3 Earnings Call ↗
MiNK Therapeutics (NASDAQ:INKT) has initiated a randomized Phase 2 trial of its investigational cell therapy agenT-797 in patients with severe acute lung injury and respiratory distress, with... 
Via MarketBeat
Topics Earnings

Performance

52-Week Range 44.5% below 52-week high
9.400
8.4852W Low 16.9352W High
1 Week 14.5% below 1-week high
9.531W Low 10.991W High

MiNK Therapeutics, Inc. - Common Stock (INKT) traded between $8.48 and $16.93 over the past 52 weeks and last traded at $9.40, 44.5% below its 52-week high. Over the past week it ranged between $9.53 and $10.99.

Past 12 Months
-9.2%
-8.1%
-14.5%
-10.6%
-15.5%
-31.3%
1W -$0.95
1M -$0.83
3M -$1.60
6M -$1.11
YTD -$1.72
1Y -$4.28

INKT was -31.3% over the past year, -10.6% over six months, -15.5% year to date, -9.2% in the last week.

12 Months vs Market
INKT
-31.3%
DIA
+8.3%
SPY
+10.4%
QQQ
+9.8%
IWM
+13.7%

Over the past 12 months INKT returned -31.3% versus DIA (Dow) +8.3%, SPY (S&P 500) +10.4%, QQQ (Nasdaq 100) +9.8% and IWM (Russell 2000) +13.7%.

Volume & Liquidity 0.18× 3-mo avg
Today 2,557 3-mo avg 14.4K
1W
10.3K
1M
11.2K
3M
14.4K
6M
19.8K
YTD
99.6K
1Y
88.9K

INKT most recently traded 2,557 shares against a 3-month average daily volume of 14.4K.

More News

Read More
News headline image
MiNK Therapeutics Reports Third Quarter 2026 Results, First Pre-Commercial Product Revenue from agenT-797, Randomized ARDS Trial Advancing, and ARPA-H Selection for Deployable Cell Therapies
From MiNK Therapeutics
Via GlobeNewswire
MiNK Therapeutics (NASDAQ:INKT) Posts Narrower-Than-Expected Q1 Loss, Advances iNKT Therapy Into Pivotal Testing ↗
Via Chartmill
News headline image
MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026)
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
MiNK Therapeutics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK (INKT) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
MiNK (INKT) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
MiNK Therapeutics Q1 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026
From MiNK Therapeutics
Via GlobeNewswire
News headline image
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
From MiNK Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is MiNK Therapeutics, Inc. - Common Stock publicly traded?
Yes, MiNK Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does MiNK Therapeutics, Inc. - Common Stock trade on?
MiNK Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MiNK Therapeutics, Inc. - Common Stock?
The ticker symbol for MiNK Therapeutics, Inc. - Common Stock is INKT on the Nasdaq Stock Market
What is the current price of MiNK Therapeutics, Inc. - Common Stock?
The current price of MiNK Therapeutics, Inc. - Common Stock is 9.400
When was MiNK Therapeutics, Inc. - Common Stock last traded?
The last trade of MiNK Therapeutics, Inc. - Common Stock was at 11/13/26 09:44 AM ET
What is the market capitalization of MiNK Therapeutics, Inc. - Common Stock?
The market capitalization of MiNK Therapeutics, Inc. - Common Stock is 323.57M
How many shares of MiNK Therapeutics, Inc. - Common Stock are outstanding?
MiNK Therapeutics, Inc. - Common Stock has 324M shares outstanding.